--- title: 'Morning Brief — Tuesday, October 20, 2026' type: 'episode' url: 'https://doc.social/episodes/morning-brief-2026-10-20' show: 'doc social Morning Brief' show_url: 'https://doc.social/podcasts/morning-brief' published: '2026-10-20' audio: 'https://media.doc.social/podcasts/morning-brief/2026-10-20.mp3' --- # Morning Brief — Tuesday, October 20, 2026 Youngstown Orthopaedic Associates joins Cleveland Clinic November 1 while Southwoods Health sues two of its surgeon-shareholders over a 30-mile non-compete · TLC BioSciences' TLC590, an extended-release ropivacaine, beats placebo and liposomal bupivacaine on 72-hour pain and opioid use in a 304-patient Phase 3 bunionectomy trial · Spine J, Virginia Mason: prone and lateral-decubitus single-level… ## Summary 3 stories this morning, for surgeons and the people who support them. - **Youngstown Orthopaedic Associates joins Cleveland Clinic November 1 while Southwoods Health sues two of its surgeon-shareholders over a 30-mile non-compete** — The practice's October 16, 2026 release says it joins Cleveland Clinic effective November 1: Poland and Warren/Howland offices become Cleveland Clinic outpatient centers, Boardman stays open for imaging as Ortho Express Care, and Dr. James Solmen retires October 31. Becker's (https://www.beckersspine.com/?p=77353) reports Southwoods Health sued shareholders Drs. David Weimer and James Jamison on October 1 in Mahoning County Common Pleas Court under a 30-mile, two-year non-compete (90-92% of Southwoods volume from that radius); Business Journal Daily (https://businessjournaldaily.com/youngstown-orthopaedic-will-join-cleveland-clinic-in-november/, October 19) reports a magistrate approved a TRO barring them from any letter of intent with Cleveland Clinic while they hold Southwoods ownership. [Source](https://www.prnewswire.com/news-releases/youngstown-orthopaedic-associates-joins-cleveland-clinic-and-dr-james-d-solmen-retires-302911527.html) - **TLC BioSciences' TLC590, an extended-release ropivacaine, beats placebo and liposomal bupivacaine on 72-hour pain and opioid use in a 304-patient Phase 3 bunionectomy trial** — October 19, 2026 GlobeNewswire release: randomized 1:1:1 (TLC590 100, liposomal bupivacaine 102, placebo 102); primary endpoint NRS-M AUC0-72h vs placebo met (p=0.0024); vs liposomal bupivacaine p=0.0202 for 72-hour pain and p=0.0177 for rescue opioids; pain separation held to 168 hours; no drug-related SAEs; NDA in preparation, no timing. Effect sizes and comparator dose not disclosed. Trial design and 304 actual enrollment confirmed on ClinicalTrials.gov NCT07222748 (https://clinicaltrials.gov/study/NCT07222748). [Source](https://www.manilatimes.net/2026/10/19/tmt-newswire/globenewswire/tlc590-achieves-statistically-significant-reductions-in-pain-and-opioid-use-versus-both-placebo-and-liposomal-bupivacaine-in-pivotal-phase-3-trial/2448497) - **Spine J, Virginia Mason: prone and lateral-decubitus single-level L4-5 LLIF cost about the same intraoperatively, but supply mix differs and biologic share ranged from about 5% to 19% across three surgeons** — Retrospective single-center cohort of 78 cases (32 lateral decubitus, 46 prone), published online October 18, 2026 (PMID 42893774). Total intraoperative cost $17,206 prone vs $16,404 lateral (p=0.462), staff cost no different; lateral had higher cost share for interbody, screws, biologics and retractors, prone for neuromonitoring and positioning; biologic share varied most between surgeons and was higher in lateral cases within surgeons. Globus previewed an XLIF prone solution for NASS 2026 (https://thespinemarketgroup.com/globus-medical-to-showcase-script-patient-specific-implants-and-new-xlif-prone-procedural-solution-at-nass-2026/). [Source](https://doi.org/10.1016/j.spinee.2026.10.008) ### Contribute to the Brief Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio). Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it. _Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._